Doctors are at an increased risk for prescription drug use, particularly opioids and benzodiazpines. This use can interfere with work function and has major potential negative implications for patient safety. Oral naltrexone, an opioid antagonist, has been used as part of a management strategy for opioid-dependent physicians. While some patients stabilize on oral naltrexone, others relapse to opioid use. An alternative method of naltrexone maintenance involves the injection or surgical insertion of a sustained release preparation of naltrexone. This approach dramatically improves compliance, removing the onus from the previously opioid impaired physician to use daily oral naltrexone.
The prevalence of alcohol and illicit drug use in medical practitioners is likely to be at least as high as that of the general population [1] [2] [3] [4] . Physicians are at an increased risk for prescription drug use, particularly opioids and benzodiazpines [4] [5] [6] , with one study indicat-ing that this may be as high as ten times that of the general population 7 .
Male doctors, particularly anaesthetists, emergency physicians, psychiatrists, surgeons and general practitioners are at highest risk of problem prescription drug use 4, 5 . This problem drug use can interfere with work function and has enormous potential negative implications for the safety of patients.
Naltrexone, a long-acting opioid antagonist which can be used orally 8 , has been used following full opioid withdrawal as part of the management of opioid-dependent physicians. Studies of the use of oral naltrexone for opioid-impaired anaesthetists and other medical specialists describe outcomes as much improved and particularly encouraging [9] [10] [11] [12] .
Another method of naltrexone delivery involves the injection or surgical insertion of a sustained release preparation of naltrexone. This approach removes the onus on patients to use daily oral naltrexone, improving compliance. In Australia, a formulation of sustained release naltrexone, suitable for subcutaneous depot administration, has been developed by GoMedical Industries Pty Ltd, Australia. In this formulation, naltrexone is encapsulated in a microsphere form by loading poly-DLlactide microspheres (Netherlands) with naltrexone and compressing the formulation into pellets. The polymer is similar to that used in surgical sutures and screws. The formulation has been used under Commonwealth Therapeutic Goods Administration Compassionate Guidelines in Western Australia, Queensland and Victoria for the treatment of approximately 700 opioid dependent patients since August 2000.
In the thirty months prior to writing this paper, four doctors received naltrexone (either oral or implant). The following describes these four cases and their outcomes to date. The relative merits of oral versus implantable naltrexone, the role of employers and the Medical Board, and the need for ongoing monitoring are also discussed.
CASE HISTORIES Case 1: General Practitioner
A general practitioner with a ten-year history of opioid abuse presented for assistance. This patient frequently changed work-place, presumably to reduce the likelihood of detection of opioid abuse. There was minimal family involvement. Initially the patient maintained that a supportive consultant and monitoring was all that was required to deal with the problem opioid use. Following several returns of opioidpositive urines, oral naltrexone treatment was commenced. Relapse back to opioid use was only identified retrospectively from urine testing. During the initial three-month period after commencement of oral naltrexone, naltrexone metabolites and an absence of opioids were confirmed with urine monitoring. However, urine samples were only provided at pre-agreed times and the opportunity for discontinuation of opioids leading up to urine monitoring was always possible.
Following this initial short period of apparent stability the patient failed to return for consultations and monitoring. This practitioner relapsed from oral naltrexone and was removed from the Medical Board register.
Case 2: Surgeon
This patient presented late in the course of illness, after several years of opioid abuse/dependence. At the time of presentation the opioid abuse was known only to the patient's family, who were supportive. This opioid-dependent surgeon was withdrawn using "rapid opioid detoxification" (ROD).
Pre-ROD medication was 250 mg celecoxib given orally as an anti-inflammatory 30 to 45 minutes prior to the commencement of detoxification, and 4 mg oral flunitrazepam (Rohypnol) immediately prior to the start of detoxification. The ROD procedure involved insertion of an intravenous (IV) line into the peripheral vein of the arm for administration of medication and fluids as necessary during ROD. Over a period of three minutes, the patient received an IV dose of 150 µg of clonidine hydrochloride in 10 ml of saline and 15 mg midazolam hydrochloride titrated IV according to level of arousal and discomfort experienced by the patient.
To control the symptoms of withdrawal the patient received 10 mg metoclopromide monohydrate orally and 2 mg odansetron IV as anti-emetics, and 0.1 mg octreotide as an anti-diarrhoerial agent. A dose of 200 µg of naloxone in a bolus solution of 5 ml saline was then injected over five minutes. Mild withdrawal symptoms were noted for approximately 15 minutes following use of naloxone. The patient was allowed to rest for approximately one hour before a second injection of 800 µg naloxone was administered. At this time no significant withdrawal or discomfort was observed. The patient was then inducted onto naltrexone maintenance by being dispensed naltrexone orally at 30-minute intervals. A 50 mg tablet of naltrexone was dissolved in 25 ml saline and given over a two-hour period. Oral fluid intake was encouraged and vital signs were monitored over the duration of ROD. The patient was subsequently instructed to take naltrexone 50 mg per day orally. Following these procedures, the patient resumed full clinical responsibilities within three weeks.
Oral naltrexone maintenance was continued for twelve months and progress was monitored via urinalysis, although urine samples were only provided sparingly and at pre-agreed times. The opportunity for discontinuation of opioid use and commencement of oral naltrexone leading up to times of urine monitoring was always possible. Following this initial apparent period of stabilization, this patient withdrew from monitoring despite repeated clinic attempts to have them attend for follow-up appointments. This patient has continued in medical practice, but is known to have relapsed from oral naltrexone to morphine use.
Case 3: Hospital Resident/General Practitioner
This patient had a ten-year history of intermittent opioid abuse and presented late in the course of the illness. There was limited family support. At the time of first presentation this practitioner had been de-registered. This patient underwent ROD as described in "Case 2" without any complications and commenced oral naltrexone the same day.
Although there appeared to be a good response initially, relapse occurred approximately four weeks following oral naltrexone treatment commencement. This was not identified until approximately seven weeks, despite regular urine monitoring. It was retrospectively suspected that this practitioner provided urine samples from others as his own. This patient again underwent ROD as described above without complication and again commenced oral naltrexone. Urine drug monitoring was again established and the patient appeared to stabilize for a four-month period.
In the following 12 months this patient failed to return for follow-up. During this period the patient was re-registered to medical practice. Shortly after reregistration they re-commenced opioid use, supplies being obtained by writing scripts in the names of patients. Following the discovery of this practice, they re-presented and a 3.4 g naltrexone implant was inserted within hours of the initial phone contact. Implantable naltrexone was used under Commonwealth Therapeutic Goods Administration Compassionate Guidelines.
Unfortunately the history of script falsification led to fraud charges and a jail sentence. This was despite effective treatment of their opioid seeking behaviour for a period of two months following naltrexone implant. The significant community damage that occurred in the months prior to the second presentation and initiation of naltrexone implant was such that it is likely this practitioner will not return to medical practice for some years.
Case Four: Anaesthetist
This patient had a ten year history of intermittent opioid abuse managed by a psychiatrist with expertise in alcohol and drug dependence. There was good family support. The patient presented to the naltrexone clinic late in the course of the illness at a time when colleagues and the Medical Board were calling for limitations to the patient's practice.
Oral naltrexone was not considered appropriate in this case and the patient agreed to have a naltrexone implant and naltrexone blood monitoring, with a view to keeping the Medical Board and medical colleagues informed. The Medical Board made treatment and ongoing monitoring of blood naltrexone a requirement for continuing registration and return to work.
A month's leave was organised for the period of treatment and initial monitoring. Initially this anaesthetist underwent ROD and had a naltrexone 3.48 g implant placed subcutaneously in his lower abdomen. As with Case 3, a naltrexone implant was used under Commonwealth Therapeutic Goods Administration Compassionate Guidelines.
Following the implant and establishment of a monitoring procedure, the patient was allowed to continue medical practice and reported being able to handle ampoules of pethidine without any thoughts related to their opioid-use behaviour.
Serial blood levels confirmed naltrexone levels at above 2 ng/ml which are adequate to antagonise high opioid doses. A second implant (3.28 g) was inserted four months after the initial implant with a third implant of 5.1g implanted nine months later (13 months post initial implant). Blood naltrexone and 6-β-naltrexol levels associated with this patient to 13 months post initial implant are shown in Figure 1 .
The Medical Board was kept fully informed and monitoring of blood naltrexone levels will continue as a condition of ongoing employment. It is expected that this management will need to be continued for a number of years.
DISCUSSION

Use of an opioid antagonist
The use of an opioid antagonist, such as naltrexone, in treating the opioid-dependent or opioidimpaired practitioner is particularly attractive for a number of reasons.
Firstly, return to work for most physicians, particularly anaesthetists and intensive care physicians, necessitates exposure to and use of opioid-based preparations. Restriction of access to these drugs would be impractical. Naltrexone reduces the craving for opioids as well as blocking their effects. These two factors should discourage use of opioids.
Secondly, so long as naltrexone compliance is ensured, the managing physician, employer and Medical Board can be assured that the previously opioid impaired dependent practitioner is not practising while under the influence of opioids and therefore public safety is not compromised. Compliance with naltrexone can allow continuation of, or an early return to work.
Oral versus implantable naltrexone
The literature suggests that outcomes associated with the use of oral naltrexone in the management of opioid-impaired anaesthetists, intensive care physicians and other medical specialists have been encouraging.
Ling and Wesson 9 evaluated outcomes in 32 physicians, who received oral naltrexone as part of their management. Although for a number of physicians, relapse to opioid use was noted two to three times over a 6-to 8-month period, 20 of the 32 physicians were rated as much improved at the end of the sixmonth period. Washton et al 10 reported on 15 opioid addicted physicians who were provided with oral naltrexone as part of a highly structured abstinence orientated program. These physicians received weekly oral naltrexone of 100 mg Monday and Wednesday and 150 mg Friday. Eleven of the 15 physicians completed six months oral naltrexone and were still opioid free and practising medicine at 12 months. Two of the 15 discontinued oral naltrexone during the six months, but remained opioid free. It is inferred that these two relapsed following the six month period. Of the two remaining physicians, one returned to dependent opioid use and the other was admitted to hospital for a manic episode. Roth et al 12 reported on seventeen nurses, two anaesthetic nurses and one pharmacist who were opioid-dependent and whose management involved the use of an oral naltrexone regimen similar to that described by Washton et al 10 . While 12 were still abstinent at nearly two years follow-up, five had relapsed once during this period. These five were were abstinent at 34 months. Three patients left the program abruptly and were presumed to have relapsed.
The evidence from the literature suggests that oral naltrexone is beneficial as part of a management plan for many impaired physicians. It is also apparent that there is a significant incidence of relapse or failure to stabilize in opioid-impaired physicians treated with oral naltrexone. This was the case in our small series.
The problems in clinical management with oral naltrexone are ensuring compliance with the naltrexone administration and the need for frequent random urine samples to detect opioid use. This monitoring of daily oral naltrexone compliance is difficult and the potential exists for the provision of false urine samples. Consequently the treating physician does not • Naltrexone.
6-β-Naltrexone.
have enough information to be absolutely certain that the patient has remained compliant with treatment and/or free of opioids. This was apparent in the first three cases described in this paper. In Cases 1 and 2 the low frequency of, and set times for, drug urine monitoring made abstinence difficult to confirm. In Case 3 non-compliance with oral naltrexone and opioid relapse was, despite urinalysis, not detected until a number of weeks after the event. Early non-detection of return to opioid use, despite urinalysis, was also a feature of Case 1.
Although the success rate of oral naltrexone for managing opioid-dependent physicians is encouraging, the significant failure rate is still a major concern. The difficulty of identifying treatment compliance and/or opioid relapse, coupled with the potential negative effects of relapse to both the dependent clinician and patients of that clinician, are major limitations of oral naltrexone treatment. Case 4 illustrates the advantages of a naltrexone implant in ensuring compliance and eliminating opioid use. A 3.4 g naltrexone implant will maintain blood naltrexone levels above 2 ng/ml for a number of months. Blood naltrexone levels of this magnitude have been reported by several separate studies to block the effects of IV diacetylmorphine in doses ranging from 25 to 500 mg [14] [15] [16] [17] [18] .
The prolonged maintenance of blood naltrexone levels above 2 ng/ml observed in Case 4 is consistent with information already reported for the GoMedical implant 13 . Blood naltrexone levels were maintained above 2 ng/ml for an average of 165 days (5.5 months) in a cohort of heroin users following use of 3.4 g implants. Case 4 indicates that blood naltrexone levels can be maintained for longer periods by the use of sequential naltrexone implants, in this instance 9 months after the second implant.
When using implantable naltrexone, compliance can be assured by monitoring blood naltrexone levels and palpation of the implant. These methods make it almost impossible for the patient to mislead the treating physician about compliance.
Compared with oral naltrexone, we would argue that the improved compliance and prolonged effect of implanted naltrexone makes the implant the treatment of choice.
Role of Medical Boards
All Medical Boards (in Australia) and the Medical Council (in New Zealand) have developed mechanisms for dealing with confidential inquiries about one's own or a colleague's suspected impairment. Wherever possible, problem drug use is dealt with as an illness rather than an offence, with doctors regarded as impaired. Procedures are supportive and aimed towards maintaining the doctor's function at work or restoring ability to work while protecting the public. All efforts are made to rehabilitate, support and monitor so that public safety can be assured. Deregistration and disciplinary proceedings are not taken lightly and generally only occur after serious offences (e.g. supply of drugs to the illicit market) or after multiple opportunities to demonstrate improvement and stability have been offered and been unsuccessful.
Ginzburg and Glass 11 reported on the twelve-to eighteen-month outcomes of 15 opioid-addicted physicians who were treated with oral naltrexone. They noted that the most important predictor of successful outcome was unequivocal job jeopardy. This was primarily as a result of Medical Board or Medical Council involvement. Our cases also followed this pattern. The success of Case 4 was associated with Medical Board involvement whilst the withdrawal from longterm follow-up of Cases 1 and 2 was associated with a lack of Medical Board involvement. Following treatment withdrawal, both Cases 1 and 2 relapsed back to opioid use, with Case 2 continuing medical practice. Medical Board involvement is more likely to ensure follow-up by requiring this for further registration. The authors recommend that the Medical Board should be made aware of and involved in case management from the outset.
Even when the Medical Board is aware of the opioid-impaired practitioner there may be a failure to establish and enforce adequate monitoring procedures. This can lead to major negative outcomes for the practitioner, as in Case 3. In the absence of any Medical Board requirement to attend for ongoing treatment as a condition of re-registration and ongoing practice, the return of this patient to opioid use was unnoticed and unchallenged. The eventual outcome was de-registration and incarceration. Early and close collaboration between the treating doctor and the Medical Board and a Medical Board requirement for ongoing monitoring and follow-up as a condition of return to medical employment should significantly reduce the risk of this tragic outcome.
The Medical Board should take a major active role in establishing a management and monitoring plan for the opioid-impaired doctor. The treatment plan (as in Case 4) may include detoxification, support to receive a naltrexone implant, medical and psychiatric evaluation, appropriate advocacy at the workplace and monitoring of clinical activities, with appropriate conditions for registration.
